Comparative bioavailability study of two controlled-release pentoxifylline tablet preparations

Drug Dev Ind Pharm. 2000 Jul;26(7):803-7. doi: 10.1081/ddc-100101303.


The bioavailability of a generic preparation of pentoxifylline sustained-release (SR) tablet was evaluated in comparison with a proprietary product (Trental 400). For the study, 12 healthy male volunteers participated; the study was conducted according to a randomized, two-way crossover design. The bioavailability was compared using the parameters total area under the plasma level-time curve AUC0-infinity, peak plasma concentration Cmax, and time to reach peak plasma concentration Tmax. No statistically significant difference was observed between the values of the two products in all three parameters. The 90% confidence interval for the ratio of the logarithmic transformed AUC0-infinity values of the generic pentoxifylline over those of Trental 400 was found to lie between 0.83 and 1.00, while that of the parameter Cmax was between 0.91 and 1.29. In addition, elimination half-life t1/2 and apparent volume of distribution Vd were calculated. There was no statistically significant difference between the t1/2 Vd values obtained from the data of the two preparations.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Analysis of Variance
  • Area Under Curve
  • Biological Availability
  • Chromatography, High Pressure Liquid
  • Cross-Over Studies
  • Delayed-Action Preparations
  • Half-Life
  • Hematologic Agents / administration & dosage
  • Hematologic Agents / blood
  • Hematologic Agents / pharmacokinetics*
  • Humans
  • Male
  • Middle Aged
  • Pentoxifylline / administration & dosage
  • Pentoxifylline / blood
  • Pentoxifylline / pharmacokinetics*


  • Delayed-Action Preparations
  • Hematologic Agents
  • Pentoxifylline